

Selective Effects of Low-Dose D₂ Dopamine Receptor Antagonism in a Reaction-Time Task in Rats

Marianne Amalric, Ph.D., Melissa Berhow, B.S., Ilham Polis, B.S., and George F. Koob, Ph.D.

Operant responses involving a cued discrimination are sensitively disrupted by neuroleptic drugs that block dopamine (DA) receptors in the brain; however, it is not clear which DA receptor subtypes may be involved in these effects. The role of D₁ or D₂ DA receptor antagonists on the execution of a conditioned reaction-time (RT) motor task was investigated in the present study. Rats were trained to release a lever after the presentation of a visual cue within a RT limit to be reinforced by a food pellet. The D₁ receptor antagonist SCH-23390, at doses that significantly decrease the behavioral effects of cocaine, did not impair performance at any dose (5, 10, or 20 µg/kg) injected subcutaneously.

In contrast, a selective D₂ receptor antagonist raclopride (50, 100, or 200 µg/kg) induced a dose-dependent increase in the number of incorrect responses (release of the lever over the RT limit) associated with an increase in the RT. The results suggest that the dopaminergic nigrostriatal system, which has previously been shown to be specifically involved in this RT task (Amalric and Koob 1987), appears to be a sensitive site for sensorimotor integration, and that the execution of the conditioned RT motor task may depend preferentially on the activation of the dopaminergic D₂ receptors in this system. [Neuropsychopharmacology 8:195–200, 1993]

KEY WORDS: Dopamine D₁ receptors; Dopamine D₂ receptors; SCH-23390; Raclopride; Reaction-time task; Rat

The brain dopamine (DA) systems have been implicated in a variety of behaviors including self-administration of psychoactive drugs or in motor control. Neuroleptic drugs that block DA receptors in the brain (Wise 1982) suppress operant responses reinforced with food, brain stimulation, or stimulant drugs. Furthermore, dopaminergic receptor blockade or neurotoxic lesions of the brain DA system also induce motor and cognitive deficits. The subdivision of DA receptors into D₁ and

D₂ sites (Kebabian and Calne 1979) on the basis of in vitro physiological and biochemical studies has opened questions as to the functional differences of these two receptors.

Most of the neuroleptic drugs are antagonists at both receptor subtypes. However, the recently developed DA antagonist, raclopride, has a high affinity for the D₂ DA receptor and crosses the blood-brain barrier fairly easily, reaching its peak concentration at about 15 minutes after intravenous injection (Köhler et al. 1985). Raclopride has no effect on the activity of adenylate cyclase, indicating the absence of action on the D₁ receptors (Ögren et al. 1986). On the other hand, the drug SCH-23390 has a very high affinity for the DA D₁ receptor, as compared to its affinity for the D₂ receptor (Billard et al. 1984; Hyttel 1983; Hjorth and Carlsson 1988); SCH-23390 has been shown to suppress numerous DA-stimulated behaviors such as stereotypy or locomotor activity, demonstrating its dopaminergic action (for review, see Clark and White 1987). Using

From the Department of Neuropharmacology, The Scripps Research Institute, La Jolla, California; and Laboratoire de Neurobiologie Cellulaire et Fonctionnelle, CNRS, Marseille, France.

Address reprint requests: to M. Amalric, Ph.D., Laboratoire de Neurobiologie Cellulaire et Fonctionnelle, CNRS, 31 chemin J. Aiguier, 13402 Marseille Cedex 9, France.

Received November 18, 1991; revised March 24, 1992 and June 25, 1992; accepted June 30, 1992.

specific selective compounds for the D₁ or the D₂ receptor subtypes, many investigators have suggested that D₁ and D₂ receptors may interact with each other in producing a variety of responses, such as hyperactivity, stereotypy, circling, and grooming in rats (Waddington 1986).

Behavioral studies have indicated a role for the mesocorticolimbic dopaminergic system in the mediation of the pharmacological actions of psychomotor stimulants such as amphetamine or cocaine. Dopamine in the nucleus accumbens appears to be involved in the reinforcing and locomotor hyperactivity induced by psychomotor stimulants (Koob et al. 1987; Roberts et al. 1980, 1982; Yokel and Wise 1978; Le Moal and Simon 1991). Whether these behavioral effects are mediated through the activation of D₁ or D₂ DA receptors is still a matter of discussion (Koob et al. 1987; Woolverton and Virus 1989; Nakajima and Baker 1989; Acquas et al. 1989; Hiroi and White 1991). In contrast, the striatum, receiving dopaminergic afferents (the nigrostriatal DA pathway) as well as cortical and thalamic inputs, plays a crucial role in the initiation and the sequencing of conditioned motor acts (for review, see Iversen 1977).

Previous work has shown that destruction of the DA nigrostriatal pathway significantly impaired reaction-time (RT) performance (Amalric and Koob 1987). Furthermore, the blockade of the dopaminergic receptors with a D₁/D₂ receptor antagonist (haloperidol) within the striatum disrupted this RT motor task and increased RTs (Amalric and Koob 1989). The present study was designed to investigate a potential differential role of the two dopaminergic receptors D₁ and D₂ in the execution of the RT motor task. For this purpose, the effects of the D₁ receptor antagonist, SCH-23390, or the D₂ receptor antagonist, raclopride, injected subcutaneously, were measured on the performance of rats trained to release a lever in a food-motivated RT task.

MATERIALS AND METHODS

Thirty-two male albino Wistar rats (Charles River Laboratories) weighing between 160 and 180 g were maintained on a 12-hour light/dark cycle, with lights on at 7 A.M. Rats were deprived of food for 48 hours, then meal-deprived by restricting the amount of food provided to 15 to 17 g per day per rat. This restriction caused no undue stress to the animals and the animals steadily gained weight during the course of the experiment. After the completion of the experiment (2 months) rats' weight ranged from 290 to 390 g.

Procedure

As previously reported (Amalric and Koob 1987) animals are first trained to press down a lever for food




Figure 1. Schematic representation of the RT task procedure. Rats were trained to press a lever down and wait for a visual cue (a light located above the lever). The CS occurs at random after four different delays (0.25 to 1.0 sec). The animals then had to release the lever in a fast movement controlled in a RT. Reaction times were measured as the time period from the CS to the lever release. If the rat failed and released the lever before the CS (AN error), no reward was given and a new trial had to be initiated. If the rat waited for the cue, then released the lever after the RT-limit restriction (700 msec), the trial was also not rewarded. Each correct trial was reinforced with a 45-mg Noyes food pellet and the daily session ended after 100 trials.

reinforcement on a continuous reinforcement schedule (CRF). They are then conditioned to wait for a light-cue stimulus (conditioned stimulus [CS]) during a time period ranging from 0.25 to 1 second occurring at random (Figure 1). To be reinforced by a 45-mg food pellet (Noyes), the rats have to release the lever within 700 msec. Daily sessions ended after 100 trials. The results are expressed as the number of correct responses by session (release of the lever within 700 msec), and the RT was measured for each trial. The RT was the time period measured from the CS onset to the lever release, measured in milliseconds. The number of incorrect responses, either anticipatory (AN) responses (AN is the release of the lever before the CS) or long (LG) responses (LG is the release of the lever after 700 msec, with the RT also measured in milliseconds), were counted separately.

Drug Treatment

After stabilization of their performance (1 month), the animals were divided into two groups ($n = 16$ in each group). On each test day, one group was injected with one dose of a D₁ receptor antagonist (SCH-23390 at 0, 5, 10, or 20 μ g/kg, dissolved in NaCl 0.9% [saline]) and

0.1% hydrochloric acid, and the second group with a D₂ receptor antagonist (raclopride at 0, 50, 100, or 200 µg/kg, dissolved in saline vehicle) subcutaneously in a volume of 0.1 ml/100 g. Thirty minutes later all animals were tested in the RT task and their motor performance recorded. The pH of the SCH-23390 solution was readjusted to 6 to 7 with NaOH 0.1 N before each injection. Within each group, each rat was injected four times with all of the different doses tested, using a Latin-square design to control for potential order effects of repeated injection. Between each test day (separated by 2 days) all animals were pretreated with a control injection (NaCl 0.9%) and their performance recorded to test for the potential effect of the handling and injection procedure.

Data Analysis

The number of correct or incorrect (AN, LG) responses as well as RTs for correct and long trials were analyzed separately. Each parameter of the performance, measured before drug treatment (mean of the two control sessions [saline injection] preceding any test day) and during the test day, was subjected to a two-factor analysis of variance (ANOVA), with repeated measures on two factors. The drug groups (doses) constituted the independent factor, the sessions pre- and postdrug were the dependent factor. Individual means between control and drug values were compared using a paired *t*-test.

RESULTS

After training, the performance of the animals was stabilized at a level of mean correct trials by session of 54 for group I (SCH-23390) and 52 for group II (raclopride) (ranging from 21 to 82). The mean correct RT averaged 340 msec (group I) and 342 msec (group II). During baseline, incorrect responses resulted largely from a high number of AN responses (mean number of AN per session was 36 for group I and 38 for group II) rather than from LG responses over the RT limit (mean number of LG per session was 10 for both groups with a mean RT averaging 1500 msec).

The pretreatment with the D₁ DA receptor antagonist (SCH-23390, 5 to 20 µg/kg) did not modify the motor performance at any dose tested (Fig. 2). The animals performed the RT task with the same rate of correct trials as during the control sessions (data not shown).

In contrast, the pretreatment with the D₂ DA receptor antagonist (raclopride, 50 to 200 µg/kg) dose-dependently decreased the number of correct trials. Analysis of variance revealed a significant dose × pre- and posttreatment sessions interaction ($F = 14.16$, $df = 3,45$, $p < .01$). Incorrect responses mainly resulted




Figure 2. Performance of rats in the RT task, after pretreatment with SCH-23390, injected subcutaneously 30 minutes before the test. A correct trial is a lever release before the RT-limit restriction (700 msec after the CS). An AN error is a release of the lever before the visual CS. An LG error is a release of the lever after the time-limit restriction.

from an increased number of long trials as shown by a significant interaction between dose and sessions (ANOVA: $F = 21.34$, $df = 3,45$, $p < .01$) (Fig. 3). Individual comparisons of means, using a paired *t*-test, showed that the three doses tested significantly increased the number of long trials, as compared to control values. Two of the 16 animals receiving the highest doses did not reach the criterion of 100 lever presses within the session. They stopped pressing the lever after 60 trials and remained in a state of prostration away from the lever. No significant change in the correct RTs (below 700 msec) was observed after raclopride treatment, except with the lowest dose (50 µg/kg). However, the RTs of non-rewarded trials (over 700 msec) were dramatically increased in a dose-dependent manner (ANOVA: $F = 14.10$, $df = 3,45$, $p < .01$) as shown in Figure 4. The RTs were increased up to 2500 msec for the highest dose of raclopride.

DISCUSSION

The present results show that doses of the D₁ receptor antagonist SCH-23390 that significantly decrease the




Figure 3. Performance of rats in the RT task after pretreatment with raclopride injected subcutaneously 30 minutes before the test. A correct trial is a lever release before the RT-limit restriction (700 msec after the CS). An AN error is a release of the lever before the visual CS. An LG error is a release of the lever after the time-limit restriction. Asterisks indicate significant difference from control values ($p < .05$, paired t -test) following significant ANOVA.

reinforcing effects or the locomotor stimulation induced by cocaine (Koob et al. 1987; Cabib et al. 1991) and *d*-amphetamine in rats (Mailman et al. 1984) do not impair performance of an appetitive simple RT motor task. However, the selective D₂ receptor antagonist raclopride in doses of 50, 100, and 200 µg/kg induced a dose-dependent disruption of the same task. This disruption was characterized by decreases in the number of correct responses that were wholly attributable to increases in the time to release the lever after the cue.

The ability of raclopride (50 to 300 µg/kg) and SCH-23390 (5 to 20 µg/kg) to produce catalepsy has been tested using the horizontal bar. As previously shown by others, SCH-23390 did not elicit catalepsy at the three doses tested. The ED₅₀ to produce catalepsy, calculated by others, was shown to vary between 20 to 80 µg/kg (Morelli and Di Chiara 1985; Meller et al. 1985). Raclopride at low doses (50 and 100 µg/kg) did not produce catalepsy either, whereas higher doses were found to be cataleptogenic (A. Ouagazzal et al., unpublished




Figure 4. Effect of raclopride pretreatment on RT. Reaction time (in msec \pm SEM) was measured from the CS onset to the lever release. Correct RTs occurred before the RT-limit restriction (*top*), incorrect RTs occurred after the RT limit. Asterisks indicate significant difference from control values ($p < .05$, paired t -test, following significant ANOVA).

results). This latter effect could explain the behavior of the two animals that did not complete the full session under the effect of the highest dose of raclopride in the present study. However, it should be stressed that the animals are food-deprived in our behavioral conditions and are thus less sensitive to the hypokinetic effect of raclopride.

The blockade of the D₂ receptors by noncataleptic doses of raclopride in our behavioral situation results in a motor deficit, expressed by an increase in RTs. However, the hypothesis of a possible reduced "reinforcement value" of the food reward cannot be ruled out as it could also result in an impairment of the motor performance. Nevertheless, an "extinction-like" response (increase in the number of lever releases followed by a decrease in performance) would be expected in this case. This was not observed in the present study.

The change in performance induced by raclopride resembles closely the deficits in RT performance previously observed with the mixed D₁/D₂ antagonist α -flupenthixol (Amalric and Koob 1987) and systemic haloperidol (unpublished data). Perhaps more importantly,

this same profile of increases in RT was observed after both DA depletions of the corpus striatum (Amalric and Koob 1987) and intracaudate infusions of haloperidol (Amalric and Koob 1989). A similar increase in operant response duration was observed by others after systemic injections of haloperidol at low doses (Liao and Fowler 1990; Fowler et al. 1986; Meck 1986). These motor deficits in response initiation resemble the symptoms of Parkinson's disease and presumably reflect an impairment of DA transmission within the striatum resulting in extrapyramidal motor effects. Thus it appears that systemic injection of low doses of raclopride can effect a blockade of DA function sufficient to block RT performance, a task mediated by the nigrostriatal DA system.

There is some evidence from neurochemical studies that D₂ antagonists at low doses may preferentially affect the nigrostriatal system. It is striking to note that tritiated ligands of the same DA antagonists used in the present study show that there is a higher relative binding of raclopride in the corpus striatum (Köhler et al. 1985) and a higher relative binding of SCH-23390 in the nucleus accumbens in the rat (A. Pert, personal communication). Furthermore, autoradiographic studies have also revealed a lateral to medial gradient of D₂-receptor density in the rat striatum (Joyce et al. 1985), which corresponds to anatomical and biochemical differences in the striatum, such as a higher cholinergic activity in the lateral striatum. This acetylcholine-rich lateral part of the striatum also receives a cortical innervation from the sensorimotor cortex. Altogether, these results suggest a direct relationship between the D₂ receptors and sensorimotor functions of the striatum (Joyce et al. 1985), although a difference in the relative density of the D₁ and D₂ receptors, as demonstrated by binding studies in different brain structures, does not necessarily imply a functional role.

A preferential involvement of D₂ agonists or antagonists in the expression of nigrostriatal dopaminergic functions is also supported by behavioral experiments. Infusion of a D₂ DA receptor agonist, quinpirole, intracerebroventricularly into rats with 6-hydroxydopamine (6-OHDA) lesions of the midbrain DA system produces more stereotyped behavior than intracerebroventricular infusions of a D₁ agonist, SKF-38393, and conversely intraaccumbens infusions of SKF-38393 were more effective than quinpirole in eliciting locomotor activity in these rats (Breese et al. 1987). Similar results have been seen with microinjections of SKF-38393 and quinpirole into the ventrolateral striatum (Delfs and Kelley 1990). Consistent with these observations, SCH-23390 has recently been shown to block the hyperlocomotion produced by cocaine, whereas selective D₂ antagonists only blocked cocaine-induced locomotion at hypokinetic doses (Cabib et al. 1991).

Clearly, the impairment of the RT task controlled

by dopaminergic activity in the corpus striatum would be dependent on the dose of the drugs employed. Higher doses of SCH-23390 clearly produce pronounced motor disturbances and catalepsy (Ioro et al. 1983; Creese and Chen 1985; Hjorth and Carlsson 1988), and animals will completely stop responding in any operant situation. In contrast, lower doses of SCH-23390 within the same dose range as tested in the present study have been found to selectively reverse DA-mediated behaviors, known to involve mesolimbic DA hyperactivity. For example, SCH-23390 (3 to 20 µg/kg) significantly reduced the stimulant effect of cocaine on locomotion (Cabib et al. 1991) and the hyperlocomotor activity following apomorphine injection in rats with 6-OHDA lesion of the mesolimbic terminals in the nucleus accumbens (Amalric et al. 1987; Mailman et al. 1984). Furthermore, the rewarding properties of psychostimulants (cocaine and *d*-amphetamine), which are thought to reflect an activation of the mesolimbic DA system, are also blocked by low doses of SCH-23390 (5 to 40 µg/kg) (Koob et al. 1987; Hiroi and White 1991).

The possibility of selectively affecting a given function of the striatal or mesolimbic DA system by systemic injections of a selective receptor subtype antagonist has important implications for the therapeutic use of these compounds. For example, there is some evidence to suggest that chronic treatment with D₁ antagonists does not produce the acute extrapyramidal syndrome observed with D₂ antagonists (Coffin et al. 1989). Thus at the low end of the dose-effect functions it may be possible to selectively access the function of the nigrostriatal or mesolimbic systems and affect their respective therapeutic effects.

ACKNOWLEDGMENTS

This is publication number 7124NP from The Scripps Research Institute. This research was supported by National Institute for Drug Abuse Grant DA04398 to George F. Koob. Marianne Amalric was supported by a fellowship from the "Fondation pour la Recherche Médicale," France. The authors thank Robert Lintz for excellent technical assistance with computer programming and electronics. We thank the Molecular and Experimental Medicine Word Processing Department for their help in manuscript preparation.

REFERENCES

- Acquas E, Carboni E, Leone P, Di Chiara G (1989): SCH 23390 blocks drug-conditioned place-preference and place-aversion: Anhedonia (lack of reward) or apathy (lack of motivation) after dopamine-receptor blockade. *Psychopharmacology* 99:151-155
- Amalric M, Koob GF (1987): Depletion of dopamine in the caudate nucleus but not in nucleus accumbens impairs reaction time performance in rats. *J Neurosci* 7:2129-2134

- Amalric M, Koob GF (1989): Dorsal pallidum as a functional motor output of the corpus striatum. *Brain Res* 483: 389–394
- Amalric M, Koob GF, Creese I, Swerdlow NR (1986): "Selective" D₁ and D₂ receptor antagonists fail to differentially alter supersensitive locomotor behavior in the rat. *Life Sci* 39:1985–1993
- Billard W, Ruperto V, Crosby G, Ioro LC, Barnett A (1984): Characterization of the binding of ³H-SCH 23390, a selective D₁ receptor antagonist ligand, in rat striatum. *Life Sci* 35:1885–1893
- Breese GR, Duncan GE, Napier TG, Bondy SC, Ioro LC, Mueller RA (1987): 6-Hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D₁ and D₂ dopamine agonists into the nucleus accumbens and striatum without changing dopamine antagonists binding. *J Pharmacol Exp Ther* 240:167–176
- Cabib S, Castellano C, Cestari V, Filibeck V, Puglisi-Allegra S (1991): D₁ and D₂ receptor antagonists differently affect cocaine-induced locomotor hyperactivity in the mouse. *Psychopharmacology* 105:335–339
- Clark D, White FJ (1987): Review: D₁ dopamine receptor—The search for a function: A critical evaluation of the D₁/D₂ dopamine receptor classification and its functional implications. *Synapse* 1:347–388
- Coffin VL, Latranyl NB, Chipkin RF (1989): Acute extrapyramidal syndrome in cebus monkeys: Development mediated by dopamine D₂ but not D₁ receptors. *J Pharmacol Exp Ther* 249:769–774
- Creese I, Chen A (1985): Selective D₁ dopamine receptor increases following chronic treatment with SCH 23390. *Eur J Pharmacol* 109:127–128
- Delfs JM, Kelley AE (1990): The role of D₁ and D₂ dopamine receptors in oral stereotypy induced by dopaminergic stimulation of the ventrolateral striatum. *Neuroscience* 39:59–67
- Fowler SC, LaCerra MM, Ettenberg A (1986): Effects of haloperidol on the biophysical characteristics of operant responding: Implications for motor and reinforcement processes. *Pharmacol Biochem Behav* 25:791–796
- Hiroi N, White NM (1991): The amphetamine conditioned place preference: Differential involvement of dopamine receptor subtypes and two dopaminergic terminal areas. *Brain Res* 552:141–152
- Hjorth S, Carlsson A (1988): In vivo receptor binding neurochemical and functional studies with the dopamine D₁ receptor antagonist SCH 23390. *J Neural Transm* 72:83–97
- Hyttel J (1983): SCH 23390—the first selective dopamine D₁ antagonist. *Eur J Pharmacol* 91:153–154
- Ioro LC, Barnett A, Leitz FH, Houser VP, Korduba CA (1983): SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. *J Pharmacol Exp Ther* 226:462–468
- Iversen SD (1977): Brain dopamine system and behavior. In Iversen LL, Iversen SD, Snyder SH (eds), *Handbook of Psychopharmacology, Drug, Neurotransmitters and Behavior*, Vol. 8. New York, Plenum, pp 333–374
- Joyce JN, Loeschen SK, Marshall JF (1985): Dopamine D₂ receptors in rat caudate-putamen: The lateral to medial gradient does not correspond to dopaminergic innervation. *Brain Res* 338:209–218
- Kebabian JW, Calne DB (1979): Multiple DA receptors for dopamine. *Nature* 277:93–96
- Köhler C, Hall H, Ögren SO, Gawell L (1985): Specific in vitro and in vivo binding of ³H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D₂ receptors in the rat brain. *Biochem Pharmacol* 34:2251–2259
- Koob GF, Le HT, Creese I (1987): D₁ receptor antagonist SCH 23390 increases cocaine self-administration in the rat. *Neurosci Lett* 79:315–320
- Le Moal M, Simon H (1991): Mesocorticolimbic dopaminergic network: Functional and regulatory roles. *Physiol Rev* 71:155–234
- Liao RM, Fowler SC (1990): Haloperidol produces within-session increments in operant response duration in rats. *Pharmacol Biochem Behav* 36:199–201
- Mailman RB, Schulz DW, Lewis MH, Staples L, Rollema H, Dehaven DL (1984): SCH 23390: A selective D₁ dopamine antagonist with potent D₂ behavioral actions. *Eur J Pharmacol* 101:159–160
- Meck WH (1986): Affinity for the dopamine D₂-receptor predicts neuroleptic potency in decreasing the speed of an internal clock. *Pharmacol Biochem Behav* 25:1185–1189
- Meller E, Kuga S, Friedhoff AJ, Goldstein M (1985): Selective D₂ dopamine receptor agonists prevent catalepsy induced by SCH 23390, a selective D₁ antagonist. *Life Sci* 36:1857–1864
- Morelli M, Di Chiara G (1985): Catalepsy induced by SCH 23390 in rats. *Eur J Pharmacol* 117:179–185
- Nakajima S, Baker JD (1989): Effects of D₂ dopamine receptor blockade with raclopride on intracranial self-stimulation and food-reinforced operant behavior. *Psychopharmacology* 97:330–333
- Ögren SO, Hall H, Köhler C, Magnusson O, Sjöstrand SE (1986): The selective dopamine D₂ receptor antagonist raclopride discriminates between dopamine-mediated motor functions. *Psychopharmacology* 90:287–294
- Roberts DCS, Koob GF (1982): Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental area in rats. *Pharmacol Biochem Behav* 17:901–904
- Roberts DCS, Koob GF, Klonoff P, Fibiger HC (1980): Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens. *Pharmacol Biochem Behav* 12:781–787
- Waddington JL (1986): Behavioral correlates of the action of selective D₁ dopamine receptor antagonists: Impact of SCH 23390 and SKF 83566, and functionally interactive D₁/D₂ receptor systems. *Biochem Pharmacol* 35:3661–3667
- Wise RA (1982): Neuroleptics and operant behavior: The anhedonia hypothesis. *Behav Brain Sci* 5:39–87
- Woolverton WL, Virus RM (1989): The effects of a D₁ and a D₂ dopamine antagonist on behavior maintained by cocaine or food. *Pharmacol Biochem Behav* 32:691–697
- Yokel RA, Wise RA (1978): Amphetamine-type reinforcement by dopamine agonists. *Psychopharmacology* 58:289–296